Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : wla(warner lambert) -- Ignore unavailable to you. Want to Upgrade?

To: Ted Downs who wrote (120)	12/1/1997 11:58:00 PM
From: Zoltan!	Respond to of 942

I do not think or believe that Glaxo tried to undermine troglitazone for competitive reasons, just as I would not want to accuse WLA of minimizing dangers because their future hangs so much on that drug. First of all, troglitazone is not a drug WLA created, it licenses and markets the drug, just like Glaxo. In fact, I believe that Glaxo's license is actually more valuable that WLA's, since it covers Europe and some other countries. Second, Glaxo's proprietary drug is still in testing. Therefore, it would not only be unethical but also foolish for Glaxo to undermine the drug for any reason other than that they stated, health concerns. Furthermore, it is also unclear whether Glaxo's actions were required by the British drug regulatory agency, which "said in a statement, "Overall, it is considered that, based on present information, the risks of ... therapy outweigh the potential benefits." Regards